Adenocarcinoma × 90 days × Clear all
NCT03093116 2026-04-03

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 5 FDA
NCT07124000 2026-03-31

DP-04

AstraZeneca

Recruiting
100 enrolled